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Background: Heart Failure Society of America and American College of Cardiology/American Heart Association guidelines support use of 
ultrafiltration therapy (UF) for acute decompensated heart failure (ADHF) with volume overload. At St Luke’s Hospital, UF is prescribed by the Heart 
Failure Management Program using Aquapheresis (AQ) by Aquadex. We evaluated the risk of bleeding associated with anticoagulation used during AQ 
by assessing transfusion requirements.
Methods: Data were extracted by the retrospective chart review of admissions with AQ from December 2008 and November 2010. IRB exemption 
was granted. Using weight based heparin or argatroban protocol, infusion was initiated without a loading dose in warfarin treated patients. Warfarin 
was not discontinued. Among the 180 AQ performed, 42 received blood transfusions during the hospitalization. Of these, 25 were during or <24 
hours post AQ (Group1) and 17 transfusions were temporally unrelated to AQ (Group2). Co-morbidities were similar in both groups.
Results: Group 1: n=25; Mean age = 78 (+/- 7.8) years. Average hemoglobin levels at admission, transfusion and discharge were 8.38, 7.75 and 
9.14 gm/dl. Warfarin therapy was concomitant in 10. Five had bleeding episodes due to recurrent gastrointestinal bleeding, 2 were on warfarin. One 
patient had hematuria post Foley catheter insertion prior to AQ and was excluded from the evaluation. None required altering AQ due to bleeding. 
Other 19 transfusions were for anemia of chronic disease. Group 2: n=17; Mean age = 72 (+/- 8.7) years. Average hemoglobin at admission, 
transfusion and discharge were 9.76, 7.58, and 9.0 gm/dl, 7 were on warfarin therapy. There were five bleeding episodes; due to recurrent 
gastrointestinal bleeding (3), retroperitoneal hematoma (1) and alveolar hemorrhage (1); 2 were on warfarin. There was no significant difference in 
transfusion requirements between the two groups (t statistic= 0.70, p = 0.49). We acknowledge the small sample size.
Conclusion: In our experience, anticoagulation associated with UF by AQ for ADHF does not increase bleeding risk as assessed by transfusion 
requirements.
